Key result
A six-week perioperative course of dipyridamole and aspirin significantly improved the patency of prosthetic femorodistal bypass grafts compared to control (85% vs 53%, P=0.005).
Why the study?
Does a short perioperative course of aspirin and dipyridamole improve the patency of femorodistal bypass grafts?
Population
148 femorodistal bypass grafts
Comparison
Dipyridamole 200 mg twice daily for 48 hours… vs Control group (no specific placebo mentioned)
Design
RCT, Randomized to act as controls or to receive treatment
Follow-up
1 year
Authors
Loading...
Perioperative dipyridamole-aspirin may improve prosthetic femorodistal bypass outcomes; extends RCT evidence toward vein-graft patency equivalence.
RCT (n=148)
randomized
Does a short perioperative course of aspirin and dipyridamole improve the patency of femorodistal bypass grafts?
Absolute Event Rate: 85% vs 53%
p-value: p=0.005
A six-week perioperative course of dipyridamole and aspirin significantly improves the patency of prosthetic femorodistal bypass grafts, allowing it to approach that of autogenous vein grafts.
Clyne et al. (1987) conducted an RCT in femorodistal bypass grafts (n=148). Aspirin and dipyridamole vs. Control was evaluated on Patency of prosthetic grafts (p=0.005). A six-week perioperative course of dipyridamole and aspirin significantly improved the patency of prosthetic femorodistal bypass grafts compared to control (85% vs 53%, P=0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: